Most people think “patent life” is a fixed number. In the GCC, it’s not.
If you’re a pharma executive, investor, or in-house counsel, you already know the headline: patents have a term. But in the Gulf Cooperation Council (GCC), the real question isn’t…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “improving” the drug. They’re extending it. Here are 4 signals to watch.
In pharma, the most expensive word in the room is often the quietest one: extension.
A competitor doesn’t need to invent a brand-new product to protect reven…

Biopharma BizDev teams don’t lose deals because they’re not smart. They lose deals because they’re late.
Late to the data. Late to the narrative. Late to the regulatory reality. And—more often than you’d think—late to the packaging clock.
In drug devel…

OpenAI’s “GPT for Life Sciences” is getting a lot of attention—but the real question for investors, pharma leaders, and biotech operators isn’t whether the model is impressive. It’s what it actually changes in the drug development value chain.
Because …

Fatigue is a common side effect of Lipitor, a medication used to lower cholesterol levels and prevent heart disease. According… https://www.Drugchatter.com/chat/16688/do-you-often-feel-tired-after-taking-lipitor/

Yervoy, also known as ipilimumab, is a medication used to treat melanoma. It has been on the market since March 2011 and… https://www.Drugchatter.com/chat/23203/any-news-on-yervoy-s-patent-expiration/

Most pharma teams are using patent expiry intelligence too late. That’s why they’re always “reacting,” not winning.
Here’s the uncomfortable truth: by the time many companies map patent cliffs, build outreach lists, and draft biosimilar launch plans, t…

Europe’s drug patent system: how long protection lasts—and where it quietly breaks down
Drugmakers love certainty. Investors love timelines. Patients deserve access. But in Europe, the question isn’t just how long a drug is protected—it’s how protectio…

Drug discovery timelines are getting longer—and the cost of waiting is rising. The industry has spent years optimizing molecules, assays, and trials, but the bottleneck is increasingly coordination: turning fragmented data, shifting hypotheses, and ite…